DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Darapladib is an investigational drug.
There have been 19 clinical trials for Darapladib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Atherosclerosis, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are GlaxoSmithKline, National Institute on Aging (NIA), and National Heart, Lung, and Blood Institute (NHLBI).
Recent Clinical Trials for Darapladib
|Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)||GlaxoSmithKline||Phase 1|
|Darapladib China PK||GlaxoSmithKline||Phase 1|
|Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects||GlaxoSmithKline||Phase 1|